Today, a Director at United Therapeutics (NASDAQ: UTHR), Richard Giltner, sold shares of UTHR for $419.2K.
See today’s analyst top recommended stocks >>
UTHR’s market cap is $5.64B and the company has a P/E ratio of 7.97. Currently, United Therapeutics has an average volume of 325.5K.
Based on 5 analyst ratings, the analyst consensus is Hold with an average price target of $139.50, reflecting a -10.0% downside. Four different firms, including Barclays and Credit Suisse, currently also have a Sell rating on the stock.
The insider sentiment on United Therapeutics has been negative according to 92 insider trades in the past three months. This sentiment is lower than the average sentiment of company insiders in this sector.
Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
United Therapeutics Corp. biotechnology company, which engages in the development and commercialization of products for patients with chronic and life-threatening diseases. It markets and sells commercial therapies to treat pulmonary arterial hypertension and high-risk neuroblastoma.
